Beneficial effect of prolyl oligopeptidase inhibition on spatial memory in young but not in old scopolamine-treated rats

被引:42
作者
Jalkanen, Aaro J.
Puttonen, Katja A.
Venalainen, Jarkko I.
Sinerva, Veijo
Mannila, Anne
Ruotsalainen, Sirja
Jarho, Elina M.
Wallen, Erik A. A.
Mannisto, Pekka T.
机构
[1] Univ Kuopio, Dept Pharmacol & Toxicol, FIN-70211 Kuopio, Finland
[2] Univ Kuopio, Dept Pharmaceut Chem, FIN-70211 Kuopio, Finland
[3] Univ Helsinki, Div Pharmacol & Toxicol, Helsinki, Finland
关键词
D O I
10.1111/j.1742-7843.2006.00021.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effects of a novel prolyl oligopeptidase (POP) inhibitor KYP-2047 on spatial memory of young (3-month-old) and old (8- to 9-month-old) scopolamine-treated rats (0.4 mg/kg intraperitoneally) was investigated in the Morris water maze. In addition, the concentrations of promnesic neuropeptide substrates of POP, substance P and neurotensin in various brain areas after acute and chronic POP inhibition were measured in young rats. In addition, inositol-1,4,5-trisphosphate (IP3) levels were assayed in rat cortex and hippocampus after effective 2.5-day POP inhibition. KYP-2047 (1 or 5 mg/kg 30 min. before daily testing) dose-dependently improved the escape performance (i.e. latency to find the hidden platform and swimming path length) of the young but not the old rats in the water maze. POP inhibition had no consistent effect on substance P levels in cortex, hippocampus or hypothalamus, and only a modest increase in neurotensin concentration was observed in the hypothalamus after a single dose of KYP-2047. Moreover, IP3 concentrations remained unaffected in cortex and hippocampus after POP inhibition. In conclusion, the behavioural data support the earlier findings of the promnesic action of POP inhibitors, but the mechanism of the memory-enhancing action remains unclear.
引用
收藏
页码:132 / 138
页数:7
相关论文
共 40 条
[1]   Alzheimer's disease and the basal forebrain cholinergic system:: relations to β-amyloid peptides, cognition, and treatment strategies [J].
Auld, DS ;
Kornecook, TJ ;
Bastianetto, S ;
Quirion, R .
PROGRESS IN NEUROBIOLOGY, 2002, 68 (03) :209-245
[2]   SUBSTANCE-P-LIKE IMMUNOREACTIVITY IS REDUCED IN ALZHEIMERS-DISEASE CEREBRAL-CORTEX [J].
BEAL, MF ;
MAZUREK, MF .
NEUROLOGY, 1987, 37 (07) :1205-1209
[3]   Effect of S 17092, a novel prolyl endopeptidase inhibitor, on substance P and α-melanocyte-stimulating hormone breakdown in the rat brain [J].
Bellemère, G ;
Morain, P ;
Vaudry, H ;
Jégou, S .
JOURNAL OF NEUROCHEMISTRY, 2003, 84 (05) :919-929
[4]   Effect of neuropeptides on cognitive function [J].
Bennett, GW ;
Ballard, TM ;
Watson, CD ;
Fone, KCF .
EXPERIMENTAL GERONTOLOGY, 1997, 32 (4-5) :451-469
[5]   Proline specific peptidases [J].
Cunningham, DF ;
O'Connor, B .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 1997, 1343 (02) :160-186
[6]   Applications of the Morris water maze in the study of learning and memory [J].
D'Hooge, R ;
De Deyn, PP .
BRAIN RESEARCH REVIEWS, 2001, 36 (01) :60-90
[7]   CENTRAL TARGET FOR THE BEHAVIORAL-EFFECTS OF VASOPRESSIN NEUROPEPTIDES [J].
DEWIED, D ;
GAFFORI, O ;
VANREE, JM ;
DEJONG, W .
NATURE, 1984, 308 (5956) :276-278
[8]  
Freed AL, 2001, ELECTROPHORESIS, V22, P3778, DOI 10.1002/1522-2683(200109)22:17<3778::AID-ELPS3778>3.0.CO
[9]  
2-E
[10]   PROLYL ENDOPEPTIDASE - INHIBITION INVIVO BY "N-BENZYLOXYCARBONYL-PROLYL-PROLINAL [J].
FRIEDMAN, TC ;
ORLOWSKI, M ;
WILK, S .
JOURNAL OF NEUROCHEMISTRY, 1984, 42 (01) :237-241